Ruan Yuyi, Chen Yutong, Huang Naya, Wang Dan, Xu Yuzhu, Fan Jinjin, Chen Wei, Wang Xin
Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
NHC Key Laboratory of Clinical Nephrology (Sun Yat-Sen University) and Guangdong Provincial Key Laboratory of Nephrology, Guangzhou, 510080, China.
Int J Med Sci. 2025 Apr 22;22(10):2298-2307. doi: 10.7150/ijms.111843. eCollection 2025.
Long-term blood pressure variability (BPV) reflects fluctuations in BP over time, which may indicate instability in precise blood pressure control. We conducted a post hoc analysis of the data from the SPRINT (Systolic Blood Pressure Intervention Trial) to assess the effect and associated variables of BPV on the renal prognosis of patients with hypertension. Excluding patients with CKD, the systolic blood pressure (SBP) at the 1, 6, and 12 follow-up months were employed to calculate the SBP coefficient of variation (CV) which represented BPV. Patients were divided into four groups based on the quartiles of BPV, namely Q1 to Q4. Group Q4 patients had higher baseline SBP. Multiple regression identified age, sex, treatment, current smoker, SBP, diastolic blood pressure (DBP), renin-angiotensin-system inhibitors (RASi), β-receptor antagonists, calcium channel blockers (CCBs), and other medications use were factors associated with BPV. The survival analysis showed that group Q4 had significantly more renal outcome events, and BPV was independently associated with the risk of renal outcome events (HR = 1.38, 95% CI: 1.23 - 1.54, < 0.001). There was a direct correlation between the BPV and risk of renal outcomes when BPV exceeded 0.037. In addition, the RASi preference group reported a significantly higher incidence of renal outcome events compared to the non-preference group (log-rank test χ² = 6.218, = 0.013) and exhibited a tendency towards higher BPV. High BPV is an independent risk factor for renal outcome events in hypertensive aging patients. The preference of RASi use can increase renal outcome events, but is not related to the rise in BPV. These findings suggest that in elderly hypertensive patients with elevated BPV, the potential risks of RASi-associated renal outcomes may outweigh its established benefits, necessitating cautious consideration of alternative antihypertensive strategies.
长期血压变异性(BPV)反映了血压随时间的波动情况,这可能表明精确血压控制存在不稳定性。我们对收缩压干预试验(SPRINT)的数据进行了事后分析,以评估BPV对高血压患者肾脏预后的影响及相关变量。排除慢性肾脏病(CKD)患者后,采用1、6和12个月随访时的收缩压(SBP)来计算代表BPV的SBP变异系数(CV)。根据BPV的四分位数将患者分为四组,即Q1至Q4。Q4组患者的基线SBP较高。多元回归分析确定年龄、性别、治疗、当前吸烟者、SBP、舒张压(DBP)、肾素 - 血管紧张素系统抑制剂(RASi)、β受体拮抗剂、钙通道阻滞剂(CCB)以及其他药物的使用是与BPV相关的因素。生存分析表明,Q4组的肾脏结局事件显著更多,并且BPV与肾脏结局事件的风险独立相关(风险比[HR] = 1.38,95%置信区间[CI]:1.23 - 1.54,P < 0.001)。当BPV超过0.037时,BPV与肾脏结局风险之间存在直接相关性。此外,RASi偏好组的肾脏结局事件发生率显著高于非偏好组(对数秩检验χ² = 6.218,P = 0.013),并且呈现出BPV较高的趋势。高BPV是老年高血压患者肾脏结局事件的独立危险因素。RASi的使用偏好会增加肾脏结局事件,但与BPV的升高无关。这些发现表明,在BPV升高的老年高血压患者中,RASi相关肾脏结局的潜在风险可能超过其既定益处,因此有必要谨慎考虑替代的降压策略。